Search research articles
Contact Us
Filters
Showing results (151-160 of 190) with videos related to
Page
of 19
Sort By:
Circulation
|
December 1, 1977
Suppression of ventricular ectopic depolarizations by tocainide
R L Woosley, D G McDevitt, A S Nies, et al.
The Journal of Biological Chemistry
|
July 25, 1985
Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism
L M Distlerath, P E Reilly, M V Martin, et al.
Pharmacogenetics
|
December 11, 1999
Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world
H G Xie, C M Stein, R B Kim, et al.
Clinical Pharmacology and Therapeutics
|
October 1, 1985
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
K Nakamura, F Goto, W A Ray, et al.
Clinical Pharmacology and Therapeutics
|
February 1, 1978
Biological determinants of propranolol disposition in man
D M Kornhauser, A J Wood, R E Vestal, et al.
Clinical Pharmacology and Therapeutics
|
March 1, 1986
Co-inheritance of the polymorphic metabolism of encainide and debrisoquin
R L Woosley, D M Roden, G H Dai, et al.
Cancer Research
|
January 1, 1984
Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients
K R Hande, P J Wedlund, R M Noone, et al.
Clinical Pharmacology and Therapeutics
|
November 1, 1991
Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans
J H Schellens, H Ghabrial, H H van der Wart, et al.
Pharmacogenetics
|
August 1, 1994
Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer
C M Fleming, R Persad, A Kaisary, et al.
The American Journal of Clinical Nutrition
|
June 1, 1979
Effect of acute alcohol ingestion on plasma pyridoxal 5'-phosphate
T H Parker, J P Marshall, R K Roberts, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 190) with videos related to
Sort By:
Page
of 19
Circulation
|
December 1, 1977
Suppression of ventricular ectopic depolarizations by tocainide
R L Woosley, D G McDevitt, A S Nies, et al.
The Journal of Biological Chemistry
|
July 25, 1985
Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism
L M Distlerath, P E Reilly, M V Martin, et al.
Pharmacogenetics
|
December 11, 1999
Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world
H G Xie, C M Stein, R B Kim, et al.
Clinical Pharmacology and Therapeutics
|
October 1, 1985
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations
K Nakamura, F Goto, W A Ray, et al.
Clinical Pharmacology and Therapeutics
|
February 1, 1978
Biological determinants of propranolol disposition in man
D M Kornhauser, A J Wood, R E Vestal, et al.
Clinical Pharmacology and Therapeutics
|
March 1, 1986
Co-inheritance of the polymorphic metabolism of encainide and debrisoquin
R L Woosley, D M Roden, G H Dai, et al.
Cancer Research
|
January 1, 1984
Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients
K R Hande, P J Wedlund, R M Noone, et al.
Clinical Pharmacology and Therapeutics
|
November 1, 1991
Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans
J H Schellens, H Ghabrial, H H van der Wart, et al.
Pharmacogenetics
|
August 1, 1994
Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer
C M Fleming, R Persad, A Kaisary, et al.
The American Journal of Clinical Nutrition
|
June 1, 1979
Effect of acute alcohol ingestion on plasma pyridoxal 5'-phosphate
T H Parker, J P Marshall, R K Roberts, et al.
Page
of 19